← Leaderboards
Matthew B Rettig
Brentwood Biomedical Research Institute
$4,044,112
Attributed
$4,044,112
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $321.7K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,044,112 · 5
VA$0 · 5
By mechanism
R01$2,442,000 · 2
P50$1,416,065 · 2
R21$186,047 · 1
I01$0 · 5
Top collaborators
- Nicholas George Nickols4 shared
- Isla Pearl Garraway2 shared
- Beatrice S Knudsen2 shared
- Anant Madabhushi2 shared
- Rudolph C Johnson1 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMolecular TargetMalignant Neoplasm Of ProstateBaseMalignant NeoplasmsCharacteristicsResistanceCancer PatientMolecularMaleIn VivoInhibitor/AntagonistResponseTranscription FactorGrowthGene ExpressionBiochemicalProteinsPharmaceutical PreparationsClinicEffective TherapyVeteransCancer EtiologyIn Vitro
Grant awards (34)
Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)$0
I01 · FY2025 · VA
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation$0
I01 · FY2024 · VA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2024 · VA · contact PI
Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)$0
I01 · FY2024 · VA
Project 2: Developing an N-terminal inhibitor of the androgen receptor$246,117
P50 · FY2023 · CA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2023 · VA · contact PI
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation$0
I01 · FY2023 · VA · contact PI
Project 2: Developing an N-terminal inhibitor of the androgen receptor$303,330
P50 · FY2022 · CA · contact PI
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation$0
I01 · FY2022 · VA · contact PI
Project 2: Developing an N-terminal inhibitor of the androgen receptor$297,413
P50 · FY2021 · CA · contact PI
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation$0
I01 · FY2021 · VA · contact PI
Project 2: Developing an N-terminal inhibitor of the androgen receptor$271,789
P50 · FY2020 · CA · contact PI
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation$0
I01 · FY2020 · VA · contact PI
Project 2: Developing an N-terminal inhibitor of the androgen receptor$297,416
P50 · FY2019 · CA · contact PI
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma$0
I01 · FY2019 · VA · contact PI
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma$0
I01 · FY2018 · VA · contact PI
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma$0
I01 · FY2017 · VA · contact PI
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor$261,450
R01 · FY2016 · CA · contact PI
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma$0
I01 · FY2016 · VA · contact PI
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor$261,450
R01 · FY2015 · CA · contact PI
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer$0
I01 · FY2015 · VA · contact PI
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer$0
I01 · FY2015 · VA · contact PI
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor$253,607
R01 · FY2014 · CA · contact PI
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor$245,763
R01 · FY2013 · CA · contact PI
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer$0
I01 · FY2013 · VA · contact PI
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor$261,450
R01 · FY2012 · CA · contact PI
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer$0
I01 · FY2012 · VA · contact PI
Targeting Androgen Receptor Activity in Prostate Cancer$91,655
R21 · FY2007 · CA · contact PI
Increased IL6 Transcription by HHV8$227,280
R01 · FY2006 · CA · contact PI
Targeting Androgen Receptor Activity in Prostate Cancer$94,392
R21 · FY2006 · CA · contact PI
Increased IL6 Transcription by HHV8$232,750
R01 · FY2005 · CA
Increased IL6 Transcription by HHV8$232,750
R01 · FY2004 · CA
Increased IL6 Transcription by HHV8$232,750
R01 · FY2003 · CA
Increased IL6 Transcription by HHV8$232,750
R01 · FY2002 · CA